Stay updated on IBI310 Combo vs Sorafenib in HCC Clinical Trial
Sign up to get notified when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.

Latest updates to the IBI310 Combo vs Sorafenib in HCC Clinical Trial page
- Check6 days agoChange DetectedThe history now includes a new entry for Revision: v3.5.5, and the previous Revision: v3.5.4 entry has been removed, reflecting a small platform update to the record history display.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's revision tag moved from v3.5.3 to v3.5.4, indicating a new version of the record history. This reflects an update to the page's metadata rather than changes to the underlying study data.SummaryDifference0.1%

- Check42 days agoChange DetectedThe Record History shows the latest revision updated to v3.5.3, replacing the previous v3.5.2. This indicates a new version of the study record has been published.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision: v3.5.2 was added to the record history, and revision v3.5.0 was removed.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision v3.5.0 adds Study Status, Contacts/Locations, and Study Design and marks the study as Completed; the prior update removed the Recruiting status and sponsor Innovent Biologics (Suzhou) Co. Ltd.SummaryDifference2%

- Check92 days agoChange DetectedThe record history now includes revision v3.4.3 and removes v3.4.2 from the history.SummaryDifference0.1%

Stay in the know with updates to IBI310 Combo vs Sorafenib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.